US EditionGalapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update - Galapagos (NASDAQ:GLPG)
FLANDERS, BELGIUM, JUL 23 – Galapagos secured full global rights to its cell therapy business through a royalty deal with Gilead and reported €3.1 billion in cash to support pipeline growth and strategic options.
4 Articles
4 Articles
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update - Galapagos (NASDAQ:GLPG)
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical data Strong balance sheet with €3.1 billion in…
13:24 Disappointing news continues to emerge from the chip sector, weighing on Melexis. Galapagos' half-year report doesn't yet provide clarity on the path the new management will take.
Still in flux, Galapagos hires new execs, adjusts deal with Gilead, and considers selling its cell therapy business
Galapagos, the Belgian biotech that has gone great lengths to reshape itself in recent years, is overhauling its business once again. The drug developer said Wednesday that it added two executives ...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
